Clinical Trial

To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study will evaluate the effects of nirogacestat 100 mg twice daily (BID) on the pharmacokinetics (PK) of a cytochrome P450 (CYP) cocktail.
Protocol Amendment History 2 changes
critical Trial completed 2026-05-02
notable Sponsor changed: SpringWorks Therapeutics, Inc. -> SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany 2026-05-02
Trial Details
NCT Number NCT07259330
Lead Sponsor SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Conditions Healthy
Enrollment 20 participants
Start Date 2025-10-27
Primary Completion 2026-03-27 (estimated)
Study Completion 2026-03-27 (estimated)
Updated on ClinicalTrials.gov 2026-05-01